CONDUCTOR AND ADDITION OF THE PROPERTY OF THE			Docket No					
CERTIFICATE OF MAILING BY FIRST		Docket No.						
Applicant(s): ABNEY et al.		PR60153US1						
Serial No. Filing Date	Examiner		Group Art Unit					
10/610 76	- Zanimo		1614					
1 001								
Invention:								
Invention: PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION COMPRISING LITHIUM CARBONATE,								
PROCESSES OF MAKING THE SAME, AND METHODS OF ADMINSTERING THE SAME								
INCOLUCIO OI MININIO IIII CAMAN, IN A MANAGEMENT CONTRACTOR OF THE								
			,					
I hereby certify that this IDS	(Identify type of correspondence)							
is being deposited with the United States Posta		velone :	addressed to:					
Director of the United States Patent and Trader	mark Office, P.O. Box 1450, Alexan	dria, VA	22313-1450					
on 10/6/03								
On (Date)								
(Dute)								
	(Typed or Printed Name of Pers	ounan on Mailin	a Correspondence)					
	(Typea of Trimea Name of Tels	. 1	,)					
	an	you.	nac					
	(Signature of Person Mo	ding Corr	espondence)					
		_						
Note: Each paper	r must have its own certificate of mailing	[.						
Partie	_							



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

ABNEY, et. al.

Serial No.:

10/619,766

Group Art Unit: 1614

Filed:

07/15/2003

Examiner:

For: PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION COMPRISING LITHIUM CARBONATE, PROCESSES OF MAKING THE SAME, AND METHODS OF ADMINSTERING THE SAME

Director of the United States Patent and Trademark Office Alexandria, VA 22313

INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

- [] Copies of the references were submitted in parent application Serial No. (37 CFR 1.98(d))
- [] A copy of the International Search Report which issued on International Application No. is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.
- A. [X] The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

or []

- The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).
- B. [] The Information Disclosure Statement transmitted herewith is being filed **after** three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but **before** the mailing date of either:
 - (1) a final action under § 1.113 or
 - (2) a notice of allowance under § 1.311,

whichever occurs first.

- [] Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- [] Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$240.00).
- C. [] The Information Disclosure Statement transmitted herewith is being filed after a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the

issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

- [] Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- [] Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).
- [] The petition fee set forth in $\S 1.17(i)(1)$ (\$130.00) is submitted herewith.

[X] Please charge any required fees to Deposit Account No.07-1392.

[] A duplicate copy of this paper is attached.

Respectfully Submitted,

Attorney of Record: Robert J. Smith

Registration No.: 40,820

Telephone: (919) 483-**9616**

Customer No.: 23347

FORM PTO 1449 INFORMATION DISCLOSURE STATEMENT				ATTORNEY DOCKET NO.: PR60153US APPLICANT:		SERIAL NO: 10/619,766		
OCT 0 9 2	103				FILING DATE: 07/15/2003		GROUP 1614	
V.	34 C	·	U.S. PATE	ENT D	OCUMENTS			
Examiner Initials		Patent Number	Issue Date		Name	Class	Subclass	Filing Date If Appropriate
	1	4264573	04/28/1981	/1981 POWELL et. al.				
	2	4695591	09/22/1987	HAN	INA et. al.			
	3	5300300	04/02/1994	EGI	DIO et. al.			
	4	5302398	04/12/1994		DIO et. al.		-	
	5	5445829	08/29/1995		RADISSIS et. al.			
	6	5558879	09/24/1996		N et. al.			
	7	5654005	08/05/1997	CHEN et. al.				
	8	6210710	04/03/2001	SKINNER				
	9	6358525	03/19/2002		O et. al.			
	10	6426087	07/30/2002		LAWSKI et. al.			<u> </u>
	11	6500459	12/31/2002	CHF	IABRA et. al.			
				<u> </u>				
					·			<u> </u>
				<u> </u>				ļ
				<u> </u>				<u> </u>
								<u> </u>
					on page			
			FOREIGN PA	TENT	T DOCUMENTS			
		Document Number	Publication Date		Country	Class	Subclass	Translation Yes No
	12	2016922	09/26/1979	GB				Х
	13	0093538	11/09/1983	EP				X
	14	0284849	10/05/1988	EP				X
	15	0471100	02/19/1992	EP				X
	16	9427557	12/08/1994	PCT				Х
	17	9640080	12/19/1996	PCT	-			X
·	18	9917751	04/15/1999	PCT	•			X
****					n page 2			
		OTHER DOC	UMENTS (Including A	uthor,	Title, Journal-Date, Pa	age Numbe	r, Etc.)	•
	25	United States Pa	atent Application Public	ation;	2002/0172727 A1; 11/2	21/2002; 1-6	; VALDUCCI	
	26		atistical Comparison of elopment and Industria				ease Solid Oral	Dosage
	27	Forms; Drig Development and Industrial Pharmacy; 1987; 13; 1107-1118 Jedras et. al.; In Vitro and In Vitro Release of Lithium from Lithium Sulphate-Gastrointestinal Diffusion System; Journal of Controlled Release; 1989; 9, No. 1; 13-19						
	28	De Haan et. al.; Oral Controlled Dosage Forms. A Review.; Pharmaceutisch Weekblad Scientific Edition; 1984; 6 (2); 57-67						
	29	Ansari et. al.; Studies on Oral Controlled Release Pellets of Lithium Carbonate; Indian Journal of Pharmaceutical Sciences; 2000; 62 (6); 512						
	30	Jedras et. al.; Kinetics of Lithium Release In Vitro from an Oral Therapeutic System; Farmacja Polska; 1984; 40 (8); 471-474						
	31	Janicki et. al.; M	ethod of Preparing and ase; Farmacja Polska; 2			of Pellets of	Lithium Carbon	ate with
_	32	Davis; The Designment 1987; 3 (5); 412-	gn and Evaluation of Co	ontroll	ed Release Dosage Fo	rms for Ora	Delivery; STP	Pharma;
	1	1		inued c	on page 2			
EXAMINER					. 5	DATE C	ONSIDERED	
EXAMINER	R: Initia	l if citation conside	red, whether or not citati	ion is i	n conformance with MP	EP § 609; D	raw line through	citation if not
in conforma	nce and	not considered. Inc	clude copy of this form v	with ne	at communication to the	applicant.		

FORM PTO-1449 PEROPPARATION DISCLOSURE STATEMENT				ATTORNEY DOCKET NO.: PR60153US		SERIAL NO: 10/619,766			
									APPLICANT:
					FILING DATE:		GROUP		
OCT 09 200					07/15/2003		1614		
Initials	E.		U.S. PATE	NT D	OCUMENTS				
CE TEADSONE?		_			Name			Filing Date If Appropriate	
Initials	Initials Patent Number			Issue Date		Class	Subclass	ii Appropriate	
				<u> </u>			-		
	-			 	<u> </u>				
<u> </u>									
			- · ·						
	ļ								
	L		Cont	invod.	on page				
					on page Γ DOCUMENTS				
	T	Document	Publication		DOCUMENTS	1	1	Translation	
		Number	Date		Country	Class	Subclass	Yes No	
	19	0151035	07/19/2001	PCT	•	<u> </u>		X	
	20	0151040	07/19/2001	PCT	•			X	
	21	0151041	07/19/2001	PCT				X	
	22	0166081	09/13/2001	PCT	•			X(Abstract Only)	
	23	0180824	11/01/2001	PCT				Х	
	24	0211740	02/14/2002	PCT		ļ		Х	
	<u> </u>	<u> </u>	L	<u> </u>		<u> </u>	1 .	<u> </u>	
		OTHER DOCK			on page Title, Journal-Date, Pa	ga Numba	r Ftc)		
	33				of Micalith Tablets; Farr				
· 	34	Janicki et. al.: A S	Study In Vitro of Lithiun	n Rele	ase from a Multi-Compa	artment Ga	strointestinal Dif	fusion	
		System; Farmacja	a Polska; 1989; No. 6;	382-3	87				
	35								
	36	Arancibia et. al.; Formulation and "In Vitro" Evaluation of a Controlled Release Lithium Carbonate Tablet; Anales de la Real Academia de Farmacia; 1990; 56; 333-346							
	37								
	38 Graffner et. al.; Testing Delivery Times; Manufacturing Chemist; September 1989; 50-53								
39 Jedras et. al.; Lithium Acetate Gastrointestinal Diffusion System Part 2. Lithium Acetate Multi-Unit Gastrointestinal Diffusion System: Preparation and Release Rate Studies; Pharmazie; 1990; 45; H.2; 116- 118									
-	40	Janicki et. al.; Lithium Acetate Gastrointestinal Diffusion System Part 1. Lithium Acetate Single-Unit Gastrointestinal Diffusion System: Preparation and Release Rate Studies; Pharmazie; 1990; 45; H. 1; 45-47							
	41	Ventouras; In Vit	ro Release of Lithium	Sulfate	e from Hydrophilic Matri	ces; Pharm	naceutica Acta H	lelvetiae;	
	1976; 51; 212-218 42 Graf et. al.; Pharmaceutical Presentation Forms: Yesterday-Today-Tomorrow; Pharm. Unserer Zeit; 1991;								
		20; No. 2; 64-74	Cont	inued	on page				
EXAMINER					-	DATE C	ONSIDERED		
EXAMINER	t: Initia	l if citation considered	ed, whether or not citati	on is i	n conformance with MPI	EP § 609; D	raw line through	citation if not	
in conformance and not considered. Include copy of this form with next communication to the applicant.									